A recent study conducted by experts from the School of Medicine at the University of Nottingham has shed light on the effects of stopping menopausal hormone therapy (MHT), also known as HRT, on bone fracture risk in women. The study, published in Lancet Healthy Longevity, revealed that the protective effect against bone fractures that women receive from MHT diminishes within a year of discontinuing treatment.
During menopause, women experience a decline in hormone levels, particularly estrogen, which can lead to various physical and mental symptoms. MHT is often prescribed to alleviate these symptoms, but it is also known to decrease fracture risk by strengthening bones. However, long-term use of MHT is associated with an increased risk of breast cancer and blood clots, making it an unfavorable option for extended periods.
The study, which analyzed data from 6 million women across 2,000 GP surgeries in the UK, followed fracture risk levels for up to 25 years. The researchers compared the MHT use of women who experienced fractures with that of matched controls without fractures. Lead author Dr. Yana Vinogradova highlighted the findings, stating that the protective effect of MHT diminishes within a year of discontinuation, leading to a temporary increase in fracture risk compared to non-users. However, the risk gradually decreases over time and eventually becomes lower than that of women who never used MHT.
The study also found that the observed risk pattern was consistent across different types of menopausal hormonal treatments, with the level of excess risk being influenced by the type and duration of MHT use. Dr. Vinogradova emphasized the importance of these findings in guiding discussions between doctors and patients regarding MHT treatment options and the potential changes in fracture risk after discontinuation.
The study’s results offer valuable insights into the effects of stopping MHT on bone health and emphasize the need for regular monitoring of bone health in women who discontinue treatment, especially those with additional fracture risk factors. The findings are expected to stimulate further research in this area and contribute to a better understanding of the long-term implications of MHT use on bone health.
In conclusion, the study provides important information for healthcare providers and women considering MHT treatment, highlighting the need for personalized approaches to managing menopausal symptoms and bone health. By understanding the risks and benefits associated with MHT, women can make informed decisions about their health and well-being in the post-menopausal years.
